Fidelity Enhanced International ETF
FENI - ETF AI Analysis
Top Page
Fidelity Enhanced International ETF (FENI)
FENI, the Fidelity Enhanced International ETF, has a solid overall rating, helped by strong holdings like Novartis, ASML, and Nestlé, which bring robust financial performance, healthy profitability, and generally supportive valuations that can add stability and growth potential to the fund. However, some positions such as Iberdrola, SAP, and UBS introduce risks like high debt, mixed or bearish technical signals, and leverage, while the fund’s broad exposure to international names means investors should be aware of sector and regional swings that can affect performance.
FENI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 11.80B
- Region
- Developed Markets
- Expense Ratio
- 0.28%
- Beta
- 0.77
- Issuer
- Fidelity
- Inception Date
- Nov 20, 2023
- Dividend Yield
- 3.14%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
FENI Summary
Fidelity Enhanced International ETF (FENI) is an international stock fund that aims to cover a wide range of companies outside the U.S., using Fidelity’s research to try to beat traditional market benchmarks rather than tracking a single index. It invests across many countries like Japan, the UK, Germany, and more, and spreads money over sectors such as financials, industrials, health care, and technology. Well-known holdings include Sony and Nestlé. Someone might invest in FENI to diversify beyond U.S. stocks and tap into global growth. A key risk is that international stock prices can go up and down sharply with global markets and currency swings.
How much will it cost me?
This ETF has an expense ratio of 0.28%, which means you’ll pay about $2.80 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because it uses an enhanced, actively researched strategy rather than simple passive indexing.
What would affect this ETF?
FENI could benefit if developed markets outside North America grow steadily, especially in sectors like technology, health care, and industrials where top holdings such as ASML, Roche, and Siemens may gain from innovation and global demand. On the downside, slower economic growth in Europe or Japan, rising interest rates that pressure financials, currency swings, or new regulations affecting large international companies could weigh on the ETF’s performance.
FENI Top 10 Holdings
FENI leans heavily into developed markets outside North America, with a clear tilt toward European healthcare and consumer staples plus Japanese cyclicals. ASML has been losing steam lately, so it’s no longer the main engine, while Novartis and Roche are quietly rising and helping steady returns. Nestlé adds a defensive backbone, staying relatively stable even when markets wobble. On the growth side, Japan’s Recruit Holdings has been a standout riser, but big financial names like UBS and Mitsubishi UFJ show more mixed momentum, keeping the fund’s overall performance balanced rather than explosive.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.81% | $331.84M | EUR 472.44B | 41.12% | 76Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Nestlé SA | 1.59% | $187.75M | CHF 223.09B | 8.59% | 71Outperform | |
| Novartis AG | 1.48% | $174.89M | CHF 243.98B | 26.00% | 80Outperform | |
| Iberdrola | 1.24% | $146.23M | EUR 150.89B | 26.10% | 67Neutral | |
| Sony | 1.29% | $152.30M | JPY 25.31T | -6.09% | 73Outperform | |
| Recruit Holdings Co | 1.17% | $138.02M | JPY 25.22T | 127.95% | 67Neutral | |
| SAP SE | 1.14% | $134.08M | EUR 235.26B | -2.66% | 66Neutral | |
| Rolls-Royce Holdings | 1.11% | $131.26M | GBP 109.62B | 21.21% | 71Outperform | |
| UBS Group AG | ― | ― | ― | ― | 73Outperform |
FENI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FENI, the sentiment is Negative. The current price of 38.76 is below the 20-day moving average (MA) of 39.60, below the 50-day MA of 39.89, and below the 200-day MA of 39.42, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 40.46 is Neutral, neither overbought nor oversold. The STOCH value of 38.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FENI.
FENI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $38.76 | $43.00(10.94% Upside) | $11.80B | 0.28% | 67Neutral | |
| $80.00 | $98.39(22.98% Upside) | $11.31B | 0.24% | 67Neutral | |
| $34.51 | $42.08(21.94% Upside) | $134.49M | 0.38% | 58Neutral | |
| $27.44 | $33.38(21.64% Upside) | $99.29M | 0.55% | 65Neutral | |
| $49.79 | $59.19(18.87% Upside) | $384.60M | 0.55% | 66Neutral | |
| $27.81 | $33.35(19.92% Upside) | $25.27M | 0.00% | 66Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FENI | Fidelity Enhanced International ETF | 38.76 | 5.04 | 14.93% | |
| JIRE | JPMorgan International Research Enhanced Equity ETF | 80.00 | 9.19 | 12.98% | |
| IMOM | Alpha Architect International Quantitative Momentum ETF | 34.51 | -1.29 | -3.60% | |
| QUIZ | Zacks Quality International ETF | 27.44 | 2.33 | 9.27% | |
| JIDE | JPMorgan International Dynamic ETF | 49.79 | 0.47 | 0.96% | |
| TACN | T. Rowe Price Active Core International Equity ETF | 27.81 | 2.57 | 10.20% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
